Thermo Fisher Scientific Inc
TMO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$327.00 | Npqk | Gcysyfwq |
Thermo Fisher Earnings: Demand Outlook Improves With Biotech Funding and China Recovering
We are maintaining our $600 fair value estimate for wide-moat Thermo Fisher following its first-quarter results. Organic revenue declined 4% in the quarter, in line with recent trends. The company, however, noted a moderately improved demand environment, which allowed it to slightly raise the lower end of its annual revenue guidance. We reiterate our wide moat rating.